Lung cancer

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Retrieved on: 
Friday, September 13, 2024
Well, Master of Science, BID, Patient, Therapy, Safety, BRAF, Oncology, Clinical trial, Caregiver, Webcast, PD, CCCC, ESMO, MEK, Cetuximab, Pharmacokinetics, Neoplasm, Congress, Colorectal cancer, BRAF V600, Teaching hospital, Completeness, Pancreatic cancer, RECIST, Cancer, Mutation, Liver disease, Lung cancer, EGFR, Melanoma, Vall, Pharmaceutical industry

Taken together, these data support our hypothesis that degradation may offer a new therapeutic option over inhibition for BRAF V600 mutant solid tumors,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics.

Key Points: 
  • Taken together, these data support our hypothesis that degradation may offer a new therapeutic option over inhibition for BRAF V600 mutant solid tumors,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics.
  • Prior therapy must include a BRAF inhibitor, unless access is limited by regional regulatory approvals or reimbursement.
  • Patients received a median of three prior therapies; 35 patients (97 percent) had received prior BRAF inhibitor therapy.
  • Pharmacokinetics (PK) and Pharmacodynamics (PD): Initial data demonstrating dose-dependent bioavailability and degradation of BRAF V600E protein support CFT1946 proof of mechanism.

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Retrieved on: 
Friday, September 13, 2024
Lung cancer, Research, Patient, AI, Population growth, Disease, Novartis, Cancer, ESMO, Thymoma, Health, Mortality, Oncology, NSCLC, Intelligence, European Central Bank, Longevity, Quality of life, Artificial intelligence, MD, Central bank, ECB, Arnau, History, Biotechnology, Tobacco, Congress, Risk, Competition (economics), Senior advisor, Breast, European Commission, Obesity, Hope, Doctor of Philosophy, Neoplasm, Future, Death, Ageing, Breast cancer, Civil service commission, Pharmaceutical industry

BARCELONA, Spain, Sept. 13, 2024 /PRNewswire/ -- In the framework of the European Society of Medical Oncology (ESMO) congress, held in Barcelona from September 13th to 17th, MEDSIR, a company that is part of Oncoclínicas & Co, dedicated to promoting independent clinical research in oncology internationally, hosted an informational breakfast with key players in cancer research to discuss the present and future of breast and lung cancer treatments. The discussion focused on crucial aspects and challenges for future research, including optimizing the recruitment process, the importance of early detection, access to the most innovative treatments, the promotion of disruptive, collaborative, and international research, and the incorporation of innovative technologies such as Artificial Intelligence.

Key Points: 
  • Besides new technologies, both proper prevention and early detection remain fundamental tools to stay ahead of the disease,' says Dr. Antonio Llombart-Cussac, MD, PhD, Senior Scientific Leader at MEDSIR and Head of the Medical Oncology Department at Arnau de Vilanova Hospital.
  • The synergy between our teams has been fundamental in expanding access to innovative solutions and developing clinical studies that truly impact patient care".
  • The use of innovative technology is crucial in addressing current research challenges, such as the potential to develop personalized treatments for patients.
  • The document outlines an agenda to address the multiple challenges facing the European Union, including the Biotechnology Law.

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

Retrieved on: 
Friday, September 13, 2024
Science, Research, Oncology, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Patient, ESMO, Liquid biopsy, Helmy Eltoukhy, Lung cancer, NSCLC, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024.
  • Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III.
  • Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC).
  • “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types,” said Craig Eagle, M.D., chief medical officer at Guardant Health.

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

Retrieved on: 
Friday, September 13, 2024
Moa, Poster, Lung cancer, Research, AACR, MRD, European, Patient, Physician, Consultant, ASTRO, Diagnosis, Conference, SITC, ESMO, Organization, Bone marrow, Liquid biopsy, Abstract, Breast cancer, SOHO, ASCO, Intelligence, Biomarker, ASH, Oncology nursing, Gastrointestinal cancer, LAS, Keynote, Late, Medical imaging

LAS VEGAS, Sept. 13, 2024 /PRNewswire/ -- The ESMO conference is a key event in the field of oncology, serving as a vital platform for sharing the latest breakthroughs in cancer research and treatment. Held annually, this conference provides a thorough overview of the most recent advancements across various oncology sub-specialties.

Key Points: 
  • DelveInsight's oncology consultants and analysts will be closely tracking the key oncology abstracts and datasets to watch at ESMO 2024.
  • The DelveInsight team is ready to provide exceptional coverage, engaging with experts and professionals across the oncology field.
  • Stay tuned with DelveInsight's analysis of key themes and results at our page: ESMO 2024 Conference
    We prioritize industry-sponsored and highly anticipated trial data presentations.
  • Rare Diseases Analysis : At DelveInsight, we are dedicated to providing essential reports that address the complexities of the rare cancer market.

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

Retrieved on: 
Friday, September 13, 2024
Moa, Poster, Lung cancer, Research, AACR, MRD, European, Patient, Physician, Consultant, ASTRO, Diagnosis, Conference, SITC, ESMO, Organization, Bone marrow, Liquid biopsy, Abstract, Breast cancer, SOHO, ASCO, Intelligence, Biomarker, ASH, Oncology nursing, Gastrointestinal cancer, LAS, Keynote, Late, Medical imaging

LAS VEGAS, Sept. 13, 2024 /PRNewswire/ -- The ESMO conference is a key event in the field of oncology, serving as a vital platform for sharing the latest breakthroughs in cancer research and treatment. Held annually, this conference provides a thorough overview of the most recent advancements across various oncology sub-specialties.

Key Points: 
  • DelveInsight's oncology consultants and analysts will be closely tracking the key oncology abstracts and datasets to watch at ESMO 2024.
  • The DelveInsight team is ready to provide exceptional coverage, engaging with experts and professionals across the oncology field.
  • Stay tuned with DelveInsight's analysis of key themes and results at our page: ESMO 2024 Conference
    We prioritize industry-sponsored and highly anticipated trial data presentations.
  • Rare Diseases Analysis : At DelveInsight, we are dedicated to providing essential reports that address the complexities of the rare cancer market.

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Retrieved on: 
Thursday, September 12, 2024
AACR, Pleural effusion, Patient, RAS, Safety, Unk, MAPK, Therapy, PD, Ascites, Partial, DSMB, Radiology, Hospital, Paclitaxel, Symantec Endpoint Protection, Data monitoring committee, Partnership, Gemcitabine, Pancreatic cancer, RECIST, Plasma, Mayo Clinic Cancer Center, E pluribus unum, Lung cancer, Mayo Clinic, Oncology, NSCLC, Pharmaceutical industry

The Phase 2a portion includes five arms, one of which focuses on patients with RAS mutant melanoma, another on patients with RAS mutant non-small cell lung cancer (NSCLC), and three arms focused on patients with pancreatic cancer.

Key Points: 
  • The Phase 2a portion includes five arms, one of which focuses on patients with RAS mutant melanoma, another on patients with RAS mutant non-small cell lung cancer (NSCLC), and three arms focused on patients with pancreatic cancer.
  • Immuneering previously announced that IMM-1-104 received fast track designation for the treatment of first- and second-line pancreatic cancer.
  • Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
  • Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.

OmRx Oncology Launches to Advance Investigational Oral Checkpoint Inhibitor Designed to Increase Access to Cancer Immunotherapy Worldwide

Retrieved on: 
Thursday, September 12, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, Entrepreneurship, Antibody, Patient, Safety, Gilead Sciences, Cancer, PD-1, PD-L1, Immunotherapy, Phase, Scripps Research, Scripps, Executive, Lung cancer, Global health, NSCLC, Pharmaceutical industry

The clinical-stage asset, OX-4224, discovered and initially developed by Gilead Sciences, is an investigational oral immune checkpoint inhibitor that targets the PD-1/PD-L1 pathway and will be evaluated by OmRx for the treatment of patients with non-small cell lung cancer (NSCLC).

Key Points: 
  • The clinical-stage asset, OX-4224, discovered and initially developed by Gilead Sciences, is an investigational oral immune checkpoint inhibitor that targets the PD-1/PD-L1 pathway and will be evaluated by OmRx for the treatment of patients with non-small cell lung cancer (NSCLC).
  • OmRx is wholly focused on advancing this clinical-stage program, first as a monotherapy in low and middle-income countries, and eventually, globally for potential all-oral combination therapies.
  • The company is led by a high-caliber team with expertise in cancer R&D, clinical development, entrepreneurship, and corporate development.
  • “Immune checkpoint inhibitor monoclonal antibodies represent one of the most important treatment advances in cancer in the past two decades, but they are essentially unavailable to cancer patients outside of the major commercial markets.

PhaseV Unveils Machine Learning-Powered Platform to Improve Oncology Clinical Trials

Retrieved on: 
Thursday, September 12, 2024
Patient, Clinical trial, FDA, HTE, Doctor of Philosophy, ESMO, PD-L1, Glioblastoma, Ipilimumab, Congress, Software, ChromeOS, Patient safety, Nivolumab, Machine learning, Efficacy, Metastasis, Lung cancer, NSCLC, Pharmaceutical industry

BOSTON, Sept. 12, 2024 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV platform to increase the efficiency and success rates of oncology clinical trials. AdaptV is an interactive machine learning-based simulation platform that enables drug developers to effectively design adaptive clinical trials through an intuitive and user-friendly interface.

Key Points: 
  • BOSTON, Sept. 12, 2024 /PRNewswire/ -- PhaseV , a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV platform to increase the efficiency and success rates of oncology clinical trials.
  • AdaptV is an interactive machine learning-based simulation platform that enables drug developers to effectively design adaptive clinical trials through an intuitive and user-friendly interface.
  • Used in Phase I and Phase I/II oncology clinical trials, these studies allow for faster identification of the optimal dose of a new treatment with fewer patients while maintaining patient safety.
  • In addition to adaptive trial designing, PhaseV offers a unique set of Causal-ML models for advanced clinical trial analysis.

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

Retrieved on: 
Thursday, September 12, 2024
Neoplasm, Research, DNA, MD Anderson Cancer Center, University, Patient, A-DNA, ESMO, Trial of the century, NGS, Congress, GENETICS, Machine learning, TRIDENT, Biology, Lung cancer, Oncology

BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.
  • The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
  • This innovative device has been developed as a clinical trial assay for Boundless Bio's ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on LinkedIn .

Summit Therapeutics Raises $235 Million

Retrieved on: 
Thursday, September 12, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung cancer, Summit, Security (finance), ESMO, Triple-negative breast cancer, Colorectal cancer, Sale, SMMT

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35 million shares of the Company’s common stock at $22.70 per share, the closing price on Wednesday, September 11, 2024, for aggregate gross proceeds to the Company of approximately $235 million.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35 million shares of the Company’s common stock at $22.70 per share, the closing price on Wednesday, September 11, 2024, for aggregate gross proceeds to the Company of approximately $235 million.
  • All of Summit’s Section 16 officers participated in the capital raise.
  • The remaining $156 million was raised with multiple leading biopharma institutional investors.
  • Summit has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock following the closing of the securities purchase agreement.